PATENT CLAIM ANALYSIS

Application Number: 15778067
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "304000"]

Abstract:
The present invention is effective for the treatment and relief of cough produced by posterior nasal secretion, through the use of the combination of Oximetazoline and Ipratropium. The active agents enunciated in the combination of the present invention have been used and marketed separately with different uses to those of the present invention. The oxymetazoline to eliminate nasal secretion and congestion (obstruction), and ipratropium bromide is marketed for the purpose of dilating the bronchial tubes in asthmatic patients with chronic obstructive pulmonary disease, although experimentally it has also been used to decrease nasal secretion. Both active agents, together or separately have not been used so far as antitussives intranasally. The cough produced by the posterior nasal secretion, is the most frequent cause of cough in the human being of any age, the present invention is effective for the treatment and relief of said symptom.

Claim (Index 16):
The treatment of to  claim 14 , further comprising disodium EDTA (disodium ethylenediaminetetraacetate) as a stabilizer present in a concentration of 50.0 mg/100 mL.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 93.0
- Lexical Diversity: 1.9625
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12654145', '10489655', '15459551', '13864491', '14088905']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7216954836537399
- 35 USC 102 Novelty (BERT): 0.4975395135656876
- Combined Prediction Score: 0.6992798866449348
- Mean Citation Score: 147.18320680000005
- Max Citation Score: 190.80013
- Similarity Product: 119.7328128973788

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test